Compass Therapeutics (CMPX) vs Protara Therapeutics (TARA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Protara Therapeutics (TARA) has outperformed Compass Therapeutics (CMPX) over the past year, losing 68.6% versus a loss of 85.9%. Over five years, TARA leads with a -67.8% price change compared with -78.6% for CMPX. Protara Therapeutics is the larger company by market cap ($140.4 million vs $123.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPX | TARA |
|---|---|---|
| Share price | $0.6882 | $2.28 |
| Market cap | $123.94M | $140.38M |
| 1-day change | +1.43% | -5.00% |
| YTD return | -87.18% | -57.22% |
| 1-year return | -85.87% | -68.60% |
| 5-year return | -78.63% | -67.80% |
| EPS (TTM) | $-0.46 | $-1.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-66.49M | $-57.44M |
| 52-week high | $6.88 | $7.82 |
| 52-week low | $0.57 | $2.09 |
| Distance from 52-week high | -90.00% | -70.84% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +664.31% | +1010.96% |
| Average volume | 3.88M | 1.07M |
| Shares outstanding | 180.09M | 61.57M |
| Employees | 39 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TARA has outperformed CMPX by 17.3 percentage points over the past year.
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
About Protara Therapeutics
TARA stock →Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
CMPX vs TARA FAQ
Which is bigger, Compass Therapeutics or Protara Therapeutics?
Protara Therapeutics (TARA) is larger, with a market capitalization of $140.38M compared with $123.94M for Compass Therapeutics (CMPX).
Which stock has performed better over the past year, CMPX or TARA?
TARA returned -68.60% over the past 12 months, compared with -85.87% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Compass Therapeutics and Protara Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.